Kymera Therapeutics
KYMR
164 hedge funds and large institutions have $2.7B invested in Kymera Therapeutics in 2024 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 58 increasing their positions, 45 reducing their positions, and 13 closing their positions.
268% more call options, than puts
Call options by funds: $2.73M | Put options by funds: $740K
223% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 13
75% more capital invested
Capital invested by funds: $1.54B → $2.7B (+$1.16B)
29% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 45
21% more funds holding
Funds holding: 136 → 164 (+28)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
0.86% more ownership
Funds ownership: 109.17% → 110.02% (+0.86%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$137M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$45.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$35.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$27.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$33M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.7M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$17.6M |
| 4 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$17.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$13.8M |
KYMR Hedge Fund Activity: Q1 2024 in Review
164 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q1 2024, worth a combined $2.7B — up 75% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new KYMR positions and 13 closed out — a net gain of 29 holders — while 58 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $137M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $33M sold.
- 164 institutional investors held Kymera Therapeutics (KYMR) as of Q1 2024, up from 136 in Q4 2023.
- Funds reported $2.7B of Kymera Therapeutics stock for Q1 2024, up 75% quarter-over-quarter.
- 42 funds opened new Kymera Therapeutics positions in Q1 2024 and 13 closed out, a net change of +29 holders.
- The largest Kymera Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $137M added.
- The largest Kymera Therapeutics seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $33M sold.
Based on aggregated 13F filings for Q1 2024.